AI Article Synopsis

  • Immunoglobulin M (IgM) autoantibodies to oxidation-specific epitopes (OSEs) may be present at birth and could help reduce the risk of atherosclerosis, according to experimental research.
  • A study involving 4,559 patients with acute myocardial infarction (AMI) and 4,617 controls found significantly lower IgM OSE levels in those with AMI, especially in males, smokers, and those with hypertension or diabetes.
  • Higher levels of specific IgM OSEs were linked to a reduced odds ratio of AMI, indicating that these antibodies may provide valuable insights for assessing heart disease risk.

Article Abstract

Immunoglobulin M (IgM) autoantibodies to oxidation-specific epitopes (OSEs) can be present at birth and protect against atherosclerosis in experimental models. This study sought to determine whether high titers of IgM titers to OSE (IgM OSE) are associated with a lower risk of acute myocardial infarction (AMI) in humans. IgM to malondialdehyde (MDA)-LDL, phosphocholine-modified BSA, IgM apolipoprotein B100-immune complexes, and a peptide mimotope of MDA were measured within 24 h of first AMI in 4,559 patients and 4,617 age- and sex-matched controls in the Pakistan Risk of Myocardial Infarction Study. Multivariate-adjusted logistic regression was used to estimate odds ratio (OR) and 95% confidence interval for AMI. All four IgM OSEs were lower in AMI versus controls (P < 0.001 for all). Males, smokers and individuals with hypertension and diabetes had lower levels of all four IgM OSE than unaffected individuals (P < 0.001 for all). Compared to the lowest quintile, the highest quintiles of IgM MDA-LDL, phosphocholine-modified BSA, IgM apolipoprotein B100-immune complexes, and MDA mimotope P1 had a lower OR of AMI: OR (95% confidence interval) of 0.67 (0.58-0.77), 0.64 (0.56-0.73), 0.70 (0.61-0.80) and 0.72 (0.62-0.82) (P < 0.001 for all), respectively. Upon the addition of IgM OSE to conventional risk factors, the C-statistic improved by 0.0062 (0.0028-0.0095) and net reclassification by 15.5% (11.4-19.6). These findings demonstrate that IgM OSE provides clinically meaningful information and supports the hypothesis that higher levels of IgM OSE may be protective against AMI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275726PMC
http://dx.doi.org/10.1016/j.jlr.2023.100391DOI Listing

Publication Analysis

Top Keywords

igm ose
20
myocardial infarction
12
igm
12
oxidation-specific epitopes
8
associated lower
8
lower risk
8
risk acute
8
acute myocardial
8
mda-ldl phosphocholine-modified
8
phosphocholine-modified bsa
8

Similar Publications

Article Synopsis
  • Three generations of tyrosine kinase inhibitors (TKIs) exist for ALK fusion-positive non-small cell lung cancer, but they fail to effectively address resistance, brain activity, and TRK inhibition issues.* -
  • NVL-655, a new TKI, shows superior selectivity and potency against ALK mutations, significantly outperforming current approved ALK TKIs in preclinical studies.* -
  • Preliminary results from a phase I/II trial indicate NVL-655's promise for treating heavily pretreated patients, including those with brain metastases and resistance mutations, potentially making it a fourth-generation advancement for ALK-driven cancers.*
View Article and Find Full Text PDF

Introduction: The primary analysis (median follow-up 34.9 mo across all arms) of the phase 3 POSEIDON study revealed a statistically significant overall survival (OS) improvement with first-line tremelimumab plus durvalumab and chemotherapy (T+D+CT) versus CT in patients with EGFR and ALK wild-type metastatic NSCLC (mNSCLC). D+CT had a trend for OS improvement versus CT that did not reach statistical significance.

View Article and Find Full Text PDF
Article Synopsis
  • IgMs produced by a specific subtype of B cells protect against inflammation and diet-induced atherosclerosis by inactivating harmful lipid oxidation products.
  • This study identifies human marginal zone B (MZB) cells as the main source of these protective IgMs through advanced techniques like single-cell mass cytometry and testing in humanized mice.
  • Treatment that reduces MZB cells leads to increased vascular inflammation, showing their protective role, while findings also indicate that higher MZB cell presence correlates with less severity in coronary artery disease in patients.
View Article and Find Full Text PDF

Idiopathic pulmonary fibrosis (IPF) is a morbid fibrotic lung disease with limited treatment options. The pathophysiology of IPF remains poorly understood, and elucidation of the cellular and molecular mechanisms of IPF pathogenesis is key to the development of new therapeutics. B-1 cells are an innate B cell population which play an important role linking innate and adaptive immunity.

View Article and Find Full Text PDF

Patients' selection and trial matching in early-phase oncology clinical trials.

Crit Rev Oncol Hematol

April 2024

Medical Oncology Department, Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon (CRCL), France. Electronic address:

Background: Early-phase clinical trials (EPCT) represent an important part of innovations in medical oncology and a valuable therapeutic option for patients with metastatic cancers, particularly in the era of precision medicine. Nevertheless, adult patients' participation in oncology clinical trials is low, ranging from 2% to 8% worldwide, with unequal access, and up to 40% risk of early discontinuation in EPCT, mostly due to cancer-related complications.

Design: We review the tools and initiatives to increase patients' orientation and access to early phase cancer clinical trials, and to limit early discontinuation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!